Kura Oncology Piotroski F Score

KURA
 Stock
  

USD 15.65  0.00  0.00%   

This module uses fundamental data of Kura Oncology to approximate its Piotroski F score. Kura Oncology F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Kura Oncology. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Kura Oncology financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Please see Kura Oncology Altman Z Score, Kura Oncology Correlation, Kura Oncology Valuation, as well as analyze Kura Oncology Alpha and Beta and Kura Oncology Hype Analysis.
  
Kura Oncology Total Debt is projected to increase significantly based on the last few years of reporting. The past year's Total Debt was at 6.88 Million. The current year Debt Non Current is expected to grow to about 5.4 M, whereas Debt Current is forecasted to decline to about 2.2 M. Kura Oncology Long Term Debt to Equity is projected to slightly decrease based on the last few years of reporting. The past year's Long Term Debt to Equity was at 0.008001. The current year Total Assets Per Share is expected to grow to 8.65, whereas Cash Flow Per Share is forecasted to decline to (1.69) .
At this time, it appears that Kura Oncology's Piotroski F Score is Frail. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
2.0
Piotroski F Score - Frail
1
Current Return On AssetsNegativeFocus
2
Change in Return on AssetsDecreasedFocus
3
Cash Flow Return on AssetsNegativeFocus
4
Current Quality of Earnings (accrual)ImprovingFocus
5
Asset Turnover GrowthN/AFocus
6
Current Ratio ChangeIncreaseFocus
7
Long Term Debt Over Assets ChangeHigher LeverageFocus
8
Change In Outstending SharesIncreaseFocus
9
Change in Gross MarginN/AFocus

Kura Oncology Piotroski F Score Drivers

The critical factor to consider when applying the Piotroski F Score to Kura Oncology is to make sure Kura Oncology is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Kura Oncology's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Kura Oncology's financial numbers are properly reported.
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares Diluted71.6 M66.4 M
Significantly Up
Increasing
Slightly volatile
Weighted Average Shares71.6 M66.4 M
Significantly Up
Increasing
Slightly volatile
Current Liabilities24.2 M22.5 M
Significantly Up
Increasing
Slightly volatile
Total Liabilities29.6 M27.4 M
Significantly Up
Increasing
Slightly volatile
Total Debt8.4 M6.9 M
Fairly Up
Increasing
Slightly volatile
Current Assets563.5 M522.3 M
Significantly Up
Increasing
Slightly volatile
Total Assets576.2 M534.1 M
Significantly Up
Increasing
Slightly volatile

Kura Oncology F Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Kura Oncology's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Kura Oncology in a much-optimized way.

About Kura Oncology Piotroski F Score

F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.

Book Value per Share

7.63

Kura Oncology Book Value per Share is projected to slightly decrease based on the last few years of reporting. The past year's Book Value per Share was at 7.63

Kura Oncology Current Valuation Drivers

We derive many important indicators used in calculating different scores of Kura Oncology from analyzing Kura Oncology's financial statements. These drivers represent accounts that assess Kura Oncology's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Kura Oncology's important valuation drivers and their relationship over time.
201720182019202020212022 (projected)
Net Income Per Employee(1.11 M)(1.31 M)(1.05 M)(1 M)(1.08 M)(1.16 M)
Average Assets79.18 M161.24 M232.97 M391.56 M575.09 M620.49 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(35.27 M)(62.64 M)(68.34 M)(91.65 M)(130.66 M)(134.1 M)
Earnings Before Interest Taxes and Depreciation Amortization USD(34.52 M)(59.47 M)(62.56 M)(88.85 M)(129.49 M)(132.9 M)
Earnings before Tax(35.43 M)(60.45 M)(63.14 M)(89.62 M)(130.47 M)(133.9 M)
Average Equity65.74 M143.2 M212.13 M360.74 M546.23 M589.35 M
Enterprise Value446 M519.74 M575.83 M1.79 B897.49 M846.4 M
Free Cash Flow(28.44 M)(48.66 M)(54.76 M)(72 M)(105.7 M)(108.48 M)
Invested Capital81.48 M160.15 M207.77 M308.37 M427.59 M461.35 M
Invested Capital Average65.3 M135.38 M172.27 M240.25 M489.37 M528 M
Market Capitalization462.3 M534.04 M623.08 M1.85 B931.78 M879.87 M
Tangible Asset Value95.85 M182.38 M241.97 M647.21 M534.05 M434.79 M
Working Capital84.61 M167.58 M224.04 M611.27 M499.83 M406.36 M

About Kura Oncology Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Kura Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kura Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kura Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California. Kura Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 123 people.

Kura Oncology Investors Sentiment

The influence of Kura Oncology's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Kura Oncology. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Investor biases related to Kura Oncology's public news can be used to forecast risks associated with investment in Kura Oncology. The trend in average sentiment can be used to explain how an investor holding Kura Oncology can time the market purely based on public headlines and social activities around Kura Oncology. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
Kura Oncology's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Kura Oncology's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Kura Oncology's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Kura Oncology.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Kura Oncology in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Kura Oncology's short interest history, or implied volatility extrapolated from Kura Oncology options trading.

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Kura Oncology using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Kura Oncology Altman Z Score, Kura Oncology Correlation, Kura Oncology Valuation, as well as analyze Kura Oncology Alpha and Beta and Kura Oncology Hype Analysis. You can also try Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.

Complementary Tools for analysis

When running Kura Oncology price analysis, check to measure Kura Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kura Oncology is operating at the current time. Most of Kura Oncology's value examination focuses on studying past and present price action to predict the probability of Kura Oncology's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kura Oncology's price. Additionally, you may evaluate how the addition of Kura Oncology to your portfolios can decrease your overall portfolio volatility.
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Is Kura Oncology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kura Oncology. If investors know Kura Oncology will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kura Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
1.1 B
Return On Assets
(0.17) 
Return On Equity
(0.28) 
The market value of Kura Oncology is measured differently than its book value, which is the value of Kura Oncology that is recorded on the company's balance sheet. Investors also form their own opinion of Kura Oncology's value that differs from its market value or its book value, called intrinsic value, which is Kura Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kura Oncology's market value can be influenced by many factors that don't directly affect Kura Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kura Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine Kura Oncology value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kura Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.